Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

In the past decade, substantial advances have been made in understanding the biology of
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …

Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …

Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet,
seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of …

Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …

Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in
cancer treatment that use checkpoint inhibitors,. For treatments using checkpoint inhibitors to …

Dendritic cells (DC) are professional antigen presenting cells, uniquely able to induce naïve
T cell activation and effector differentiation. They are, likewise, involved in the induction and …

Messenger RNA (mRNA)-based therapeutics hold the potential to cause a major revolution
in the pharmaceutical industry because they can be used for precise and individualized …

In humans, infections with the human coronavirus (HCoV) strains HCoV-229E, HCoV-OC43,
HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract …

Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for
harnessing the potential of a patient's own immune system to eliminate tumor cells in …